An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
Completed · Phase 2 · NCT02832167
Conditions: Cancer
At a glance
- Research payments reported, 2025
- $290
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 239
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (biological)
- Dates
- Started 2016-02-22; completion 2021-06-24
- Results posted
- Yes
The purpose of this study is to determine whether nivolumab is an effective treatment for cancer that has advanced or has spread. Various tumor types may be eligible for enrollment.
From ClinicalTrials.gov, last updated 2022-05-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $290 in research payments for this study in 2025 (1 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Minnesota Hematology / Oncology, PA $290
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.